Clinical Trials Sponsored by PETHEMA Foundation

Total 15701 results

PETHEMA Foundation

Recruiting

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Recruiting

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

Lymphoblastic Lymphoma

Spain
PETHEMA Foundation

Recruiting

Epidemiologic Registry PETHEMA LMA 2015

AML

Spain
PETHEMA Foundation

Recruiting

Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Recruiting

PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years

Acute Myeloblastic Leukemia

Spain
PETHEMA Foundation

Active, not recruiting

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Chronic Lymphocytic Leukemia

Spain
PETHEMA Foundation

Completed

Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia (LAMVYX)

Newly Diagnosed Secondary or High Risk AML

Spain
PETHEMA Foundation

Completed

Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML (FLAGINEXOR)

Acute Myeloid Leukemia

Spain
PETHEMA Foundation

Completed

CML Treated With Bosutinib After Relapse (BOSTRO)

Chronic Myeloblastic Leukaemia

Spain
PETHEMA Foundation

Completed

Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Acute Lymphobkastic Leukemia

Spain
PETHEMA Foundation

Completed

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed (LENDEXAL)

Primary Systemic Amyloidosis

Spain
PETHEMA Foundation

Completed

Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure (RENVEL)

Multiple Myeloma

Spain
PETHEMA Foundation

Completed

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Acute Myeloblastic Leukemia

Spain
PETHEMA Foundation

Completed

Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma (TaCyDexVMP7)

Multiple Myeloma

Spain
PETHEMA Foundation

Completed

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

Cytomegalovirus Infection

Spain
PETHEMA Foundation

Completed

GEM05 for Patients With Multiple Myeloma Under 65 Years (GEM05MENOS65)

Multiple Myeloma

Spain
PETHEMA Foundation

Completed

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Chronic Myeloid Leukaemia

Spain
PETHEMA Foundation

Completed

Glivec in Ph Positive Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Cromosome Philadelphia Positive

Spain
PETHEMA Foundation

Completed

Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)

Acute Promyelocytic Leukemia

Spain
PETHEMA Foundation

Not yet recruiting

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL (LALPh2022)

Lymphoblastic Leukemia | Adult ALL | Philadelphia-Positive ALL
PETHEMA Foundation

Recruiting

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Leukemia, Myeloid, Acute | De Novo | Age More 60yr

Spain
PETHEMA Foundation

Recruiting

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Acute Lymphoblastic Leukemia Ph Positive

Spain
PETHEMA Foundation

Recruiting

Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

Acute Lymphoblastic Leukemia Ph Positive

Spain
PETHEMA Foundation

Active, not recruiting

Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

Multiple Myeloma

Spain
PETHEMA Foundation

Terminated

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.

Acute Myeloid Leukemia

Spain
PETHEMA Foundation

Completed

Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

Acute Myeloblastic Leukemia

Spain
PETHEMA Foundation

Terminated

PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia (2009-009422-92)

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia (LAL-AR-N-2005)

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning (MINIALO-VELCAD)

Multiple Myeloma

Spain
PETHEMA Foundation

Completed

Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)

Acute Promyelocytic Leukemia

Spain
PETHEMA Foundation

Terminated

LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)

AML

Spain
PETHEMA Foundation

Terminated

A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF

Diabetic Patients With Critic Ischemia in Lower Limbs Who Are Administered With CD133+ Cells Mobilized by G-CSF

Spain
PETHEMA Foundation

Completed

Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma

Lymphoma | Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Completed

Treatment of Acute Myeloblastic Leukemia in Younger Patients

Acute Myeloblastic Leukemia

Spain
PETHEMA Foundation

Completed

VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma

Multiple Myeloma

Spain
PETHEMA Foundation

Completed

Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis (AMBINEB)

Acute Myeloid Leukemia | Allogeneic Haematopoietic Progenitor Cell Transplant

Spain
PETHEMA Foundation

Recruiting

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Multiple Myeloma in Relapse

Spain
PETHEMA Foundation

Recruiting

Molecular Diagnostic Platform for AML

Acute Myeloid Leukemia (AML)

Spain
PETHEMA Foundation

Recruiting

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Refractory Multiple Myeloma

Spain
PETHEMA Foundation

Recruiting

Clinical Guidelines for APL Treatment

APL

Spain
PETHEMA Foundation

Recruiting

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Acute Lymphoblastic Leukemia

Spain
PETHEMA Foundation

Active, not recruiting

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Newly Diagnosed Multiple Myeloma

Spain
PETHEMA Foundation

Active, not recruiting

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia- Binet Staging System

Spain
PETHEMA Foundation

Terminated

PETHEMA-BLIN-01/PET069014 (BLIN-01)

Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL

Spain
PETHEMA Foundation

Active, not recruiting

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia (PONALFIL)

ALL

Spain
PETHEMA Foundation

Completed

Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)

Relapsed and Refractory Multiple Myeloma

Spain

3

Subscribe